Intrinsic connectomes are a predictive biomarker of remission in major depressive disorder

• Published in: Molecular psychiatry 2020-07, Vol.25 (7), p.1537-1549
• Main Authors: Korgaonkar, Mayuresh S., Goldstein-Piekarski, Andrea N., Fornito, Alexander, Williams, Leanne M.
• Format: Article
• Language: English
• Subjects: 59; 59/36; 692/53/2422; 692/699/476/1414; Adult; Antidepressants; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Attention; Behavioral Sciences; Biological Psychology; Biomarkers; Biomarkers - metabolism; Brain - diagnostic imaging; Brain - drug effects; Brain - metabolism; Care and treatment; Citalopram; Citalopram - pharmacology; Citalopram - therapeutic use; Connectome; Depressive Disorder, Major - diagnosis; Depressive Disorder, Major - diagnostic imaging; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - metabolism; Evaluation; Female; Functional magnetic resonance imaging; Humans; Magnetic Resonance Imaging; Major depressive disorder; Male; Medicine; Medicine & Public Health; Mental depression; Neural networks; Neural Pathways - diagnostic imaging; Neurosciences; Pharmacotherapy; Psychiatry; Remission; Remission (Medicine); Remission Induction; Sensory integration; Sertraline; Sertraline - pharmacology; Sertraline - therapeutic use; Venlafaxine; Venlafaxine Hydrochloride - pharmacology; Venlafaxine Hydrochloride - therapeutic use; Young Adult
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/s41380-019-0574-2

Although major depressive disorder (MDD) is associated with altered functional coupling between disparate neural networks, the degree to which such measures are ameliorated by antidepressant treatment is unclear. It is also unclear whether functional connectivity can be used as a predictive biomarker of treatment response. Here, we used whole-brain functional connectivity analysis to identify neural signatures of remission following antidepressant treatment, and to identify connectomic predictors of treatment response. 163 MDD and 62 healthy individuals underwent functional MRI during pre-treatment baseline and 8-week follow-up sessions. Patients were randomized to escitalopram, sertraline or venlafaxine-XR antidepressants and assessed at follow-up for remission. Baseline measures of intrinsic functional connectivity between each pair of 333 regions were analyzed to identify pre-treatment connectomic features that distinguish remitters from non-remitters. We then interrogated these connectomic differences to determine if they changed post-treatment, distinguished patients from controls, and were modulated by medication type. Irrespective of medication type, remitters were distinguished from non-remitters by greater connectivity within the default mode network (DMN); specifically, between the DMN, fronto-parietal and somatomotor networks, the DMN and visual, limbic, auditory and ventral attention networks, and between the fronto-parietal and somatomotor networks with cingulo-opercular and dorsal attention networks. This baseline hypo-connectivity for non-remitters also distinguished them from controls and increased following treatment. In contrast, connectivity for remitters was higher than controls at baseline and also following remission, suggesting a trait-like connectomic characteristic. Increased functional connectivity within and between large-scale intrinsic brain networks may characterize acute recovery with antidepressants in depression.